



6/28/04

Attorney Docket No. 13952N-000220US

Form PTO-1595 (Rev. 10-02) OMB No. 0651-0027 (exp. 5/31/2002)		OFFICE OF PUBLIC RECORDS Recordation F PATEN		06-30-2004  102780109		Department of Commerce Patent and Trademark Office	
Tab settings $\Rightarrow \Rightarrow \Rightarrow \nabla$ 2004 JUN 23 AM 9:49						or copy thereof (ies)	
To the Honorable Commissioner of Patents and Trademark							
1. Name of conveying party(ies) ZymoGenetics, Inc.				Name: Novo Nordisk Health Care AG Street Address: Untere Heslibachstrasse 46 City: Zurich, Postal Code / State: Postal Code: CH-8700 Kusnacht Country: Switzerland			
Additional name(s) of conveying party(ies) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No.				Additional name(s) and address(es) attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No			
3. Nature of conveyance: <input type="checkbox"/> Assignment <input type="checkbox"/> Merger <input type="checkbox"/> Security Agreement <input type="checkbox"/> Change of Name <input checked="" type="checkbox"/> Other: Corrective Assignment							
Execution Date: <u>December 5, 2001</u>							
4. Application number(s) or patent number(s): If this document is being filed together with a new application, the execution date of the application is: A. Patent Application No(s): B. Patent No(s): 5,288,629 Additional numbers attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No							
5. Name and address of party to whom correspondence concerning document should be mailed: Name: Steven W. Parmelee TOWNSEND AND TOWNSEND AND CREW LLP Two Embarcadero Center, Eighth Floor San Francisco, California 94111-3834 (415) 576-0200				6. Total number of applications and patents involved 1 7. Total fee (37 CFR 3.41): -----\$40.00 <input type="checkbox"/> Enclosed <input checked="" type="checkbox"/> Authorized to be charged to deposit account			
				8. Deposit account number: 20-1430 (Attach duplicate copy of this page if paying by deposit account)			
DO NOT USE THIS SPACE							
9. Statement and signature. <i>To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.</i>							
Steven W. Parmelee Name of Person Signing Atty. Reg. No. 31,990		 Signature		<u>June 22, 2004</u> Date			
Total number of pages including cover sheet, attachments and documents: 7							

Mail documents to be recorded with required cover sheet information to:

Mail Stop Assignment Recordation Services
 Director of the U.S. Patent and Trademark Office
 P.O. Box 1450
 Alexandria, VA 22313-1450

06/29/2004 LIAELLER 00000103 201430 5288629
 01 FC:0021 40.00 BA

PATENT
REEL: 015503 FRAME: 0465

PATENTS ONLY

07-15-2002

Key Docket No. 13952N-000200

To the
Please reand Trademarks
or copy thereof.

102149326

1. Name of Parties conveying an interest: ZymoGenetics, Inc. 1201 Eastlake Avenue East Seattle, Washington 98101		2. Name and Address of Party receiving an interest: Novo Nordisk Health Care AG Untere Heslibachstrasse 46 CH-8700 Kusnacht Zurich, Switzerland	
3. Description of the interest conveyed: <input checked="" type="checkbox"/> Assignment <input type="checkbox"/> Change of Name <input type="checkbox"/> Other <input type="checkbox"/> Security Agreement <input type="checkbox"/> Merger			
4. Application number(s) or patent number(s). Additional sheet attached? <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No If this document is being filed together with a new application, the execution date of the application is: Title: A. Patent Application No(s) <u>5,228,629</u> <u>5,824,639</u> B. Patent No(s). JAN 18 2002			
5. Name and address of party to whom correspondence concerning document should be mailed: Steven W. Parmelee Townsend and Townsend and Crew LLP Two Embarcadero Center, 8 th Floor San Francisco, California 94111		6. Number of applications/patents involved: - 1 - 7. Amount of fee enclosed or authorized to be charged: \$80.00 8. Deposit Account No. 20-1430	
DO NOT USE THIS SPACE			
9. Date of execution of the attached document: December 5, 2001			
10. I declare under penalty of perjury under the laws of the United States of America that the foregoing is a true and correct copy of the original assignment document. Executed on <u>December 11, 2001</u> <u>Steven W. Parmelee</u> Signature Steven W. Parmelee, Reg. No. 31, 990 Name of Person Signing			

02/01/2002 AMWED1 00000093 201430 5228629
01 FC:581 80.00 CHPATENT
REEL: 015503 FRAME: 0466

ASSIGNMENT

WHEREAS, ZymoGenetics, Inc., of 1201 Eastlake Avenue East, Seattle, Washington, 98102, hereinafter referred to as "ASSIGNOR," is sole assignee of the inventors of the invention described and set forth below.

WHEREAS, Novo Nordisk Health Care AG, a Swiss corporation, located at Untere Heslibachstrasse 46, CH-8700 Kusnacht, Zurich, Switzerland, hereinafter referred to as "ASSIGNEE," is desirous of acquiring the entire interest in, to, and under the invention and application and in any Letters Patent and Registrations that may be granted on the same.

WHEREAS, (a) the ASSIGNOR is the sole registered owner of the following patents or patent applications ("the Patents"):

Australian Patent No. 651,573, issued November 15, 1994
British Patent No. 521,873, issued June 2, 1999
Canadian Patent No. 2,074,839, issued on November 14, 2001
French Patent No. 521,873, issued June 2, 1999
German Patent No. 521,873, issued June 2, 1999
Japanese Patent Application No. 3-504863, filed January 25, 1991
Swedish Patent No. 521,873, issued June 2, 1999
Swiss Patent No. 521,873, issued June 2, 1999
U.S. Patent No. 5,288,629, issued February 22, 1994
U.S. Patent No. 5,824,639, issued October 20, 1998

(b) The parties hereto have agreed that the Patents should be transferred by the ASSIGNOR to the ASSIGNEE for the consideration hereinafter set forth.

NOW THEREFORE, for good and valuable consideration, ASSIGNOR hereby sells, assigns and transfers to ASSIGNEE, its successors, legal representatives and assigns, the full and exclusive rights, titles and interests to said Letters Patent for the full term or terms for which the same may be granted.

SAID ASSIGNOR hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States of America to issue said Letters Patent to ASSIGNEE, as assignee of the entire right, title and interest in, to and under the same, for the sole use and behalf of the ASSIGNEE, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

SAID ASSIGNOR hereby covenants that we have full right to convey the entire right, title and interest herein sold, assigned, transferred and set over.

AND SAID ASSIGNOR hereby further covenants and agrees that we will, at any time, when called upon to do so by the ASSIGNEE, its successors, legal representatives, or assigns, communicate to the ASSIGNEE, its successors, legal representatives, or assigns, as the case may be, any

